Which calcium channel blocker is used in SVT management?

Enhance your paramedic skills with the Platinum Paramedic Test. Dive into comprehensive quiz formats with detailed explanations and solutions. Prepare effectively for your certification!

Multiple Choice

Which calcium channel blocker is used in SVT management?

Slow AV nodal conduction is the lever that helps terminate or control SVT when using a calcium channel blocker. Non-dihydropyridine calcium channel blockers do this by blocking the L-type calcium channels in the AV node, which reduces conduction through the node and can interrupt a reentrant circuit responsible for SVT. Diltiazem fits this role well in acute SVT management. As a non-DHP CCB, it effectively slows AV nodal conduction and can terminate AV nodal reentrant tachycardia or control the ventricular rate during atrial tachyarrhythmias. It’s often preferred in the acute setting because it provides the needed AV nodal blockade with a relatively favorable hemodynamic profile compared with verapamil, whose stronger negative inotropic effect can raise the risk of hypotension in some patients. Adenosine and esmolol work by different mechanisms (adenosine being a purinergic agent and esmolol a beta-blocker), and dihydropyridine CCBs don’t target AV nodal conduction. So, the calcium channel blocker used in SVT management is diltiazem.

Slow AV nodal conduction is the lever that helps terminate or control SVT when using a calcium channel blocker. Non-dihydropyridine calcium channel blockers do this by blocking the L-type calcium channels in the AV node, which reduces conduction through the node and can interrupt a reentrant circuit responsible for SVT.

Diltiazem fits this role well in acute SVT management. As a non-DHP CCB, it effectively slows AV nodal conduction and can terminate AV nodal reentrant tachycardia or control the ventricular rate during atrial tachyarrhythmias. It’s often preferred in the acute setting because it provides the needed AV nodal blockade with a relatively favorable hemodynamic profile compared with verapamil, whose stronger negative inotropic effect can raise the risk of hypotension in some patients. Adenosine and esmolol work by different mechanisms (adenosine being a purinergic agent and esmolol a beta-blocker), and dihydropyridine CCBs don’t target AV nodal conduction.

So, the calcium channel blocker used in SVT management is diltiazem.

More practice questions